valuation thoughts, page-200

Hi DrillDown,
Thanks for your post, like you I agree its good to have something to work from. Its much better than throwing darts at a board.

One thing however With the GBM trial and the complete lack of treatment for this form of cancer I think there may be a chance of accelerated approval if Cohorts 3 & 4 bring about the results we hope in terms of Safety profile and Efficacy. Maybe a shortened Phase 2 trial in early 2023 with approval mid 2023.

This would negate the need for future cap raisers.



Time will tell I guess.



Pete